Tonix Pharmaceuticals has crossed from serial clinical developer into commercial operator, and the second quarter is the first clean test of whether TONMYA can carry the equity. The drug is the first new fibromyalgia medicine in more than fifteen years, launched in mid-November after an August approval, and it is already the company's economic center of gravity. What changed in the quarter is not the existence of a product but the conversion of coverage and refill behavior into a sales run-rate that the market still refuses to capitalize.
TONMYA net sales nearly tripled sequentially to $11 million. Total product revenue reached $14 million once the two inherited migraine brands are included. Prescriptions doubled and refills more than tripled, which is the persistence signal a launch needs if the franchise is to fund itself. Coverage now spans a large minority of insured lives after two commercial group-purchasing contracts and broad Medicaid inclusion. A managed Medicare contract is queued for January. The counterweight is the cost of that launch. Selling expense more than doubled. First-half operating cash burn more than doubled. The auditor's going-concern language remains because cash plus a thin at-the-market program does not cover twelve months from the filing date.
The investment debate is whether TONMYA's refill and access trajectory outruns the dilution clock. Cash of $176 million and no funded debt look ample until the burn rate is annualized. Management's own runway statement only reaches early second quarter of next year. Does sequential TONMYA growth stay near the recent pace as the larger sales force arrives, or does gross-to-net pressure and a forced raise reassert the old microcap pattern?